The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: Current evidence and directions for future research

Infectious Agents and Cancer

Volumn 5, Issue 1, 2010, Pages

  Bratcher, Lara F ^a   Sahasrabuddhe, Vikrant V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CANCER GRADING; CANCER REGRESSION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COLPOSCOPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMA VIRUS INFECTION; IMMUNOCOMPETENCE; LESIONS AND DEFECTS; MIXED INFECTION; PAPANICOLAOU TEST; PRIORITY JOURNAL; REVIEW; SQUAMOUS INTRAEPITHELIAL LESION; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; WART VIRUS;

EID: 77951988818     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-5-8     Document Type: Review

References (52)

1. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. SE Hawes CW Critchlow MA Faye Niang MB Diouf A Diop P Toure A Aziz Kasse B Dembele P Salif Sow AM Coll-Seck, et al. J Infect Dis 2003 188 555 563 10.1086/376996 12898443
3. Long-term incidence of cervical cancer in women with human immunodeficiency virus. LS Massad EC Seaberg DH Watts H Minkoff AM Levine D Henry C Colie TM Darragh NA Hessol, Cancer 2009 115 524 530 10.1002/cncr.24067 19127538
4. Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population. Y Adam CJ van Gelderen G de Bruyn JA McIntyre DA Turton NA Martinson, BMC Cancer 2008 8 211 10.1186/1471-2407-8-211 18657270
5. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. KH Fife JW Wu KE Squires DH Watts JW Andersen DR Brown, J Acquir Immune Defic Syndr 2009 51 274 282 10.1097/QAI.0b013e3181a97be5 19387354
6. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. HD Strickler RD Burk M Fazzari K Anastos H Minkoff LS Massad C Hall M Bacon AM Levine DH Watts, et al. J Natl Cancer Inst 2005 97 577 586 15840880 (Pubitemid 40723785)
7. High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. A Gingelmaier T Grubert R Kaestner I Mylonas T Weissenbacher F Bergauer L Barthell K Friese, Anticancer Res 2007 27 1795 1798 17649775
8. Chapter 6: Immunosuppression and co-infection with HIV. JM Palefsky EA Holly, J Natl Cancer Inst Monogr 2003 41 46 12807944
9. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000 92 1823 1830 10.1093/jnci/92.22.1823 11078759
10. Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy. M Dorrucci B Suligoi D Serraino U Tirelli G Rezza, J Acquir Immune Defic Syndr 2001 26 377 380 11317082
11. Trends in cancer risk among people with AIDS in the United States 1980-2002. EA Engels RM Pfeiffer JJ Goedert P Virgo TS McNeel SM Scoppa RJ Biggar, AIDS 2006 20 1645 1654 10.1097/01.aids.0000238411.75324.59 16868446
12. Cancer risk in people infected with human immunodeficiency virus in the United States. EA Engels RJ Biggar HI Hall H Cross A Crutchfield JL Finch R Grigg T Hylton KS Pawlish TS McNeel JJ Goedert, Int J Cancer 2008 123 187 194 10.1002/ijc.23487 18435450
13. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. L Ahdieh-Grant R Li AM Levine LS Massad HD Strickler H Minkoff M Moxley J Palefsky H Sacks RD Burk SJ Gange, J Natl Cancer Inst 2004 96 1070 1076 15265968 (Pubitemid 39172408)
14. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. A Del Mistro R Bertorelle M Franzetti A Cattelan A Torrisi MT Giordani R Sposetti E Bonoldi L Sasset L Bonaldi, et al. Clin Infect Dis 2004 38 737 742 10.1086/381681 14986260
15. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. FB Lillo D Ferrari F Veglia M Origoni MA Grasso S Lodini E Mastrorilli G Taccagni A Lazzarin C Uberti-Foppa, J Infect Dis 2001 184 547 551 10.1086/322856 11494160
16. AIDS-related cancer and severity of immunosuppression in persons with AIDS. RJ Biggar AK Chaturvedi JJ Goedert EA Engels, J Natl Cancer Inst 2007 99 962 972 10.1093/jnci/djm010 17565153
17. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. H Minkoff L Ahdieh LS Massad K Anastos DH Watts S Melnick L Muderspach R Burk J Palefsky, AIDS 2001 15 2157 2164 10.1097/00002030-200111090-00011 11684935
18. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. K Nanda DC McCrory ER Myers LA Bastian V Hasselblad JD Hickey DB Matchar, Ann Intern Med 2000 132 810 819 10819705
19. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. L Dal Maso J Polesel D Serraino M Lise P Piselli F Falcini A Russo T Intrieri M Vercelli P Zambon, et al. Br J Cancer 2009 100 840 847 10.1038/sj.bjc.6604923 19223894
20. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. E Soncini A Zoncada V Condemi AD Antoni E Bocchialini P Soregotti, Acta Biomed 2007 78 36 40 17687815
21. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. GM Clifford J Polesel M Rickenbach L Dal Maso O Keiser A Kofler E Rapiti F Levi G Jundt T Fisch, et al. J Natl Cancer Inst 2005 97 425 432 15770006
22. Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women. I Heard V Potard D Costagliola, Antivir Ther 2006 11 1091 1096 17302379
23. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. P Paramsothy DJ Jamieson CM Heilig PC Schuman RS Klein KV Shah AM Rompalo S Cu-Uvin A Duerr, Obstet Gynecol 2009 113 26 31 19104356
24. Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era. G Sirera S Videla R Lopez-Blazquez M Llatjos A Tarrats E Castella N Grane C Alcalde C Tural C Rey-Joly B Clotet, AIDS Res Hum Retroviruses 2007 23 965 971 10.1089/aid.2006.0293 17725412
25. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. P Schuman SE Ohmit RS Klein A Duerr S Cu-Uvin DJ Jamieson J Anderson KV Shah, J Infect Dis 2003 188 128 136 10.1086/375783 12825181 (Pubitemid 36829752)
26. Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AL Moore CA Sabin S Madge A Mocroft W Reid MA Johnson, AIDS 2002 16 927 929 10.1097/00002030-200204120-00014 11919496
27. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. I Heard JM Tassie MD Kazatchkine G Orth, AIDS 2002 16 1799 1802 10.1097/00002030-200209060-00013 12218392
28. Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3. G Sirera S Videla R Lopez-Blazquez M Llatjos A Tarrats E Castella N Grane C Tural C Rey-Joly B Clotet, J Antimicrob Chemother 2008 61 191 194 10.1093/jac/dkm412 17977910
29. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. M Ferguson DE Wilkinson T Zhou, Vaccine 2009 27 337 347 10.1016/j.vaccine.2008.10.062 19007840
30. Human papillomavirus infection in HIV-infected persons. J Palefsky, Top HIV Med 2007 15 130 133 17720998
31. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. TV Ellerbrock MA Chiasson TJ Bush XW Sun D Sawo K Brudney TC Wright Jr, Jama 2000 283 1031 1037 10.1001/jama.283.8.1031 10697063
32. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Munoz, J Pathol 1999 189 12 19 10.1002/(SICI)1096- 9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
33. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. I Heard V Schmitz D Costagliola G Orth MD Kazatchkine, AIDS 1998 12 1459 1464 10.1097/00002030-199812000-00007 9727566
34. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. I Heard V Potard H Foulot C Chapron D Costagliola MD Kazatchkine, J Acquir Immune Defic Syndr 2005 39 412 418 10.1097/01.qai.0000167157.83098.60 16010162
35. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. WR Robinson CA Hamilton SH Michaels P Kissinger, Am J Obstet Gynecol 2001 184 538 543 10.1067/mob.2001.111103 11262450
36. Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease? R Meys FM Gotch CB Bunker, Br J Dermatol 2009 19709102
37. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. SD Vernon CE Hart WC Reeves JP Icenogle, Virus Res 1993 27 133 145 10.1016/0168-1702(93)90077-Z 8384765
38. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. ML Tornesello FM Buonaguro E Beth-Giraldo G Giraldo, Intervirology 1993 36 57 64 8294182
39. Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection. A Spinillo P Tenti R Zappatore F De Seta E Silini S Guaschino, Gynecol Oncol 1993 48 210 213 10.1006/gyno.1993.1035 8381376
40. The distribution of immunocompetent cells in the genital tract of HIV-positive women. A Olaitan MA Johnson A MacLean LW Poulter, AIDS 1996 10 759 764 10.1097/00002030-199606001-00010 8805867
41. Immune factors involved in the cervical immune response in the HIV/HPV co-infection. AF Nicol GJ Nuovo A Salomao-Estevez B Grinsztejn A Tristao F Russomano ESJR Lapa MP Oliveira C Pirmez, J Clin Pathol 2008 61 84 88 10.1136/jcp.2007.047290 17483251
42. Antitumour effects of antiretroviral therapy. P Monini C Sgadari E Toschi G Barillari B Ensoli, Nat Rev Cancer 2004 4 861 875 10.1038/nrc1479 15516959
43. Population-based linkage of AIDS and cancer registries: importance of linkage algorithm. D Deapen M Cockburn R Pinder S Lu AR Wohl, Am J Prev Med 2007 33 134 136 10.1016/j.amepre.2007.03.015 17673101
44. Measuring the global burden of disease and epidemiological transitions: 2002-2030. AD Lopez CD Mathers, Ann Trop Med Parasitol 2006 100 481 499 10.1179/136485906X97417 16899150
45. Global epidemiology of HIV-AIDS. SS Abdool Karim Q Abdool Karim E Gouws C Baxter, Infect Dis Clin North Am 2007 21 1 17 vii. 10.1016/j.idc.2007.01.010 17502227
46. Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. MH Mwanahamuntu VV Sahasrabuddhe KS Pfaendler V Mudenda ML Hicks SH Vermund JS Stringer GP Parham, AIDS 2009 23 1 5 10.1097/QAD.0b013e3283236e11 19279439
47. Management of cryotherapy-ineligible women in a "screen-and- treat" cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field. KS Pfaendler MH Mwanahamuntu VV Sahasrabuddhe V Mudenda JS Stringer GP Parham, Gynecol Oncol 2008 110 402 407 10.1016/j.ygyno.2008.04.031 18556050
48. HPV screening for cervical cancer in rural India. MH Mwanahamuntu VV Sahasrabuddhe GP Parham, N Engl J Med 2009 361 305 author reply 306. 19610158
49. HPV-based cervical cancer screening in a population at high risk for HIV infection. SD Womack ZM Chirenje L Gaffikin PD Blumenthal JA McGrath T Chipato S Ngwalle M Munjoma KV Shah, Int J Cancer 2000 85 206 210 10629079
50. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. S Franceschi H Jaffe, Clin Infect Dis 2007 45 510 513 10.1086/520022 17638204
51. Questions and Answers: The CIPRA HT001 Clinical Trial. http://www3.niaid.nih.gov/news/QA/CIPRA-HT01-qa.htm
52. HPTN 052: A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples. http://www.hptn.org/research-studies/hptn052.asp